Texto: 
- BCVA: 20/20 -2 OU   (low myope OU)

- color vision (PIP): 10/14 OD  11/14 OS

- red desaturation: 90% OD

- white light brightness: 75% OD

- pupils: 4->3mm OU,    2+ APD OD

- Motility: FD & V OU

- Visual Fields: gross defect to confrontation 7-9 clock hours OD; full OS

- IOP: 16 OU

- SLE: normal anterior segment OU

- DFE: 
     Lens/vitreous: clear OU 
     macula: +FLR, flat and unremarkable OU
     A/V:
        normal caliber w/o nicking, tortuosity,                     
        attenuation, or sheathing OU
     Periphery: 
        flat and unremarkable OU
     Disc: 
        0.1 C/D OU w/o pallor/heme
        slightly increased fullness/elevation OD, but      
        sharp disc margins/clearly-defined vessels
        single flat, hypopigmented lesion just inferior   
        to disc margin OD (1/5 DD)
- Trans-sphenoidal surgical debulking (uncomplicated)

- Serology:
     Bartonella
     Lyme
     RPR/FTA

- MRI orbits
Presumably new-onset, painless, diffuse R monocular field loss  w/ +APD and subtle abnormalities of R optic disc
Large intrasellar and suprasellar mass lesion
Pituitary macroadenoma - Null Cell (non-secreting)
-Optic nerve disease:
     neuropathy: compressive/infiltrative,     
     inflammatory, ischemic, toxic
     optic nerve drusen

- Retrobulbar optic neuritis 

- Neuroretinitis (Bartonella, Syphilis, Lyme)

-Intracranial Process:
     - mass (pit adenoma, meningioma, glioma,      
     craniopharygioma)
     - aneurysm (most likely ICA)
     inflammation (sarcoid, MS)

- Retinal Dystrophy/Degeneration:
     - fundus flavimaculatus
21 y.o. woman reservist, activated & deployed into Iraq in March.

Air evacuated to Germany and then subsequently to WRAMC in mid July for dyspnea.

Pulmonology evaluation made a diagnosis of asthma, and she was started on PO steroid burst w/ taper, albuterol, Advair and Singulaire.  

R-sided visual loss (OD) started shortly after initiating these asthma meds and remained stable over next 1-2 weeks.  She then reported “I can’t see person standing to my right”. 

She denied any sudden onset - but is unable to pinpoint the moment when her symptoms began nor recall what she was doing; no “falling curtain”.

- no central vision loss OU

- no vision changes OS

- no floaters, photopsia or amaurosis 

- no headache, eye pain or photophobia 

- no gross neurologic symptoms (diplopia, dysarthria, weakness, parasthesias, confusion)

- PMH/PSH: 
     recent asthma dx

- FH: 
     non-contributory

- Social Hx:
     no tobacco/rare EtOH
     1 previous sexual partner 2 years ago

- Meds:
     PO Prednisone taper (currently 20mg qd)
     Albuterol
     Singular
     Advair
     OCP 

-Allergies: 
     PCN
- 10-15% of all intracranial tumors
- normal volunteers had 10% incidence of asymptomatic adenomas by MRI

- Found in 1.5-27% of autopsy cases

Patients present with either:
     Hormonal abnormalities
     Symptoms of compressive lesion: headache, field    
     defects or cranial nerve palsies (cavernous sinus  
     invasion) 

Genetic Association:
     MEN type 1: 
          30% of patients have pit adenoma
          Triad with parathyroid and pancreatic islet           
          tumors
     GSP:
          Gene that encodes alpha-subunit of     
          GTP-binding protein Gs
          mutation leads to activation of cAMP
     Present in:
          40% of GH-secretors
          10% of null cell (non-secretors)
          6% of ACTH-secretors

Classification:
     Based on size:
          Macroadenoma > 1cm
          Microadenoma < 1cm
     Based on what the tumor secretes:
          Prolactin, gonadotropin, GH, ACTH, TSH
          nothin’ (null cell)

Surgery:
     For most non-prolactin secreting adenomas
     Usually trans-sphenoidal:
          Mortality <1%
          Common complications: nasal septal            
          perforation, ant. pit insufficiency,  
          transient diabetes insipidus, CSF leak
          Carotid injury and vision loss are RARE

     Success measures clinically and radiographically
     Normalization of hormones varies with type/size of   
     tumor
     Normalization of visual fields = 16-53%
     Improvement of visual fields = 26-70%

Treatment of Prolactinomas:
     MEDICAL (dopamine agonists)
     - PRL secretion inhibited by dopamine secretion  
     from the hypothalamus

     - Decreases tumor size      (70-90% of cases)
     - Normalizes PRL levels     (70-90% of cases)
     - Restores ovulation/menses (70-90% of cases)
     - Improves visual fields    (70-90% of cases)

     "REVERSIBLE, therefore lifelong tx is RULE"

Drugs:
     Bromocriptine (classic—used for decades)
     Side effects: N/V, dizziness, postural    
     hypotension, HA’s

Newer agents:
     Lisuride
     Pergolide
     Cabergoline

New txs for non-PRL adenomas:
     GH-secretors:
          Somatostatin analogs: octreotide & lanreotide
          Reduce GH levels in 90% of pts 
          achieve complete suppression in 50% of pts

Radiation:
     Usually reserved for residual dz or recurrence   
     after surgery
     Average total dose = 45-50 Gy
     Control rates of 85-95% @ 10 years

3 types:
     Standard
     Stereotactic fractionated
     Stereotactic radiosurgery (single dose / Gamma     
     knife)

Disadvantages:
      Slower reversal of neurologic symptoms
      Slower drop in hormonal levels
      Hypopituitarism: 50% of pts will have at least     
      one pit hormone deficiency @ 5 yrs       lifelong   
      follow-up
Secondary brain tumor:
      Risk of 1.3-1.7% @ 10 yrs
      Risk of 1.9-2.7% @ 20 yrs
      (relative risk of 9.3-16 X general population)
      Radiation-induced optic neuropathy/retinopathy
      Low risk: 0.7-2%

SRS(stereotactic radiosurgery)
       Quicker drop in hormone levels
       Adverse CNS effects in 28% of cases at 3 yrs    
       compared with 0% with FSRT3

       "NOT RECOMMENDED !!"


Keywords: 
- rare success measures clinically (0)
- heme slightly increased fullness (0)
- csf leak carotid injury (0)
- pancreatic islet tumors gsp (0)
- 4 -> 3mm ou (0)
- toxic optic nerve drusen (0)
- po steroid burst w (1)
- mri orbits presumably new (0)
- 50 gy control rates (0)
- pts achieve complete suppression (0)
- 16 x general population (1)
- “ falling curtain ”. (0)
- normal anterior segment ou (1)
- lanreotide reduce gh levels (0)
- surgery average total dose (0)
- defined vessels single flat (0)
- 10 years 3 types (0)
- albuterol singular advair ocp (0)
- 9 clock hours od (1)
- 5 yrs lifelong follow (0)
- central vision loss ou (1)
- neurologic symptoms slower drop (0)
- autopsy cases patients present (0)
- optic nerve disease (1)
- therefore lifelong tx (1)
- hormonal levels hypopituitarism (0)
- cranial nerve palsies (5)
- retrobulbar optic neuritis (1)
- white light brightness (1)
- transient diabetes insipidus (1)
- sharp disc margins (1)
- see person standing (1)
- pulmonology evaluation made (1)
- normalizes prl levels (1)
- normal caliber w (1)
- nasal septal perforation (0)
- gross neurologic symptoms (1)
- fundus flavimaculatus 21 (0)
- currently 20mg qd (1)
- classic — used (0)
- cavernous sinus invasion (0)
- sheathing ou periphery (0)
- low myope ou (1)
- clear ou macula (0)
- sided visual loss (1)
- 3 yrs compared (0)
- pip ): 10 (0)
- secondary brain tumor (1)
- po prednisone taper (1)
- hormonal abnormalities symptoms (0)
- disc margin od (1)
- unremarkable ou disc (0)
- retinopathy low risk (0)
- induced optic neuropathy (1)
- prl secretion inhibited (1)
- improves visual fields (1)
- vision changes os (1)
- tsh nothin ’ (0)
- sphenoidal surgical debulking (1)
- recent asthma dx (1)
- 14 od 11 (0)
- 10 yrs risk (0)
- pit adenoma triad (0)
- decreases tumor size (1)
- men type 1 (1)
- bartonella lyme rpr (0)
- single dose (1)
- ou w (6)
- vision loss (11)
- unremarkable ou (2)
- 16 ou (1)
- visual fields (19)
- symptoms began (5)
- slower reversal (1)
- right ”. (0)
- reported “ (1)
- quicker drop (1)
- normal volunteers (1)
- intracranial tumors (10)
- camp present (0)
- pit adenoma (2)
- 14 os (1)
- color vision (2)
- prl adenomas (1)
- tumor secretes (1)
- tumor normalization (0)
- subtle abnormalities (1)
- gross defect (1)
- elevation od (1)
- dopamine secretion (1)
- 20 yrs (2)
- 2 ou (6)
- v ou (3)
- pit insufficiency (1)
- full os (1)
- 5 dd (1)
- secretors 10 (0)
- relative risk (2)
- woman reservist (1)
- usually reserved (4)
- stereotactic radiosurgery (6)
- somatostatin analogs (3)
- social hx (6)
- side effects (8)
- retinal dystrophy (1)
- restores ovulation (1)
- residual dz (1)
- remained stable (14)
- red desaturation (1)
- recommended !!" (1)
- radiographically normalization (0)
- postural hypotension (0)
- null cell (4)
- next 1 (4)
- newer agents (1)
- mid july (1)
- likely ica (1)
- intracranial process (1)
- hypopigmented lesion (3)
- hormones varies (1)
- ha ’ (0)
- genetic association (1)
- gamma knife (35)
- field defects (7)
- eye pain (17)
- encodes alpha (1)
- dopamine agonists (1)
- common complications (6)
- asymptomatic adenomas (1)
- apd od (2)
- air evacuated (2)
- 1cm microadenoma (0)
- 1 c (174)
- pts radiation (0)
- secretors classification (0)
- 2 weeks (122)
- sudden onset (88)
- started shortly (1)
- confrontation 7 (1)
- compressive lesion (3)
- asthma meds (1)
- 1cm based (0)
- 3 (8405)
- 10 (1995)
- surgery (1277)
- patients (1457)
- od (7546)
- mri (1820)
- gh (14422)
- flat (236)
- cases (558)
- albuterol (19)
- advair (6)
- 9 (4978)
- 50 (678)
- pts (74)
- 5 (8237)
- 16 (559)
- risk (538)
- ’ (1174)
- type (949)
- taper (45)
- sphenoidal (19)
- size (636)
- neuropathy (80)
- lyme (40)
- bartonella (5)
- asthma (93)
- 1 (15898)
- secretors (4)
- 2 (13754)
- v (59120)
- started (182)
- radiation (533)
- onset (524)
- meds (87)
- compressive (47)
- based (378)
- apd (9)
- 7 (4391)
- 20 (2416)
- wramc (11)
- weakness (434)
- vitreous (11)
- uncomplicated (59)
- unable (148)
- treatment (1790)
- trans (1361)
- tortuosity (16)
- tobacco (47)
- syphilis (27)
- subunit (5)
- subsequently (152)
- srs (1)
- sle (269)
- singulaire (1)
- serology (9)
- secreting (20)
- sarcoid (356)
- rule (333)
- reversible (46)
- recurrence (207)
- recall (38)
- r (401870)
- pupils (64)
- psh (36)
- prolactinomas (2)
- prolactin (35)
- pmh (154)
- pinpoint (4)
- photopsia (1)
- photophobia (35)
- pcn (3)
- parathyroid (253)
- parasthesias (8)
- pallor (13)
- painless (102)
- octreotide (14)
- non (3524)
- nicking (1)
- neuroretinitis (1)
- n (440951)
- ms (3435)
- motility (25)
- mortality (75)
- moment (6)
- menses (25)
- meningioma (444)
- medical (618)
- mass (5255)
- march (49)
- macroadenoma (50)
- lens (9)
- ischemic (166)
- iraq (16)
- iop (1167)
- initiating (5)
- inflammatory (519)
- inflammation (226)
- infiltrative (56)
- inferior (623)
- incidence (176)
- improvement (161)
- hypothalamus (21)
- headache (758)
- gtp (4)
- gonadotropin (8)
- glioma (411)
- germany (7)
- gene (1895)
- fta (5)
- fsrt3 (1)
- found (642)
- flr (1)
- floaters (1)
- fh (30)
- fd (92)
- either (205)
- dyspnea (137)
- dysarthria (21)
- drugs (71)
- dizziness (85)
- disadvantages (5)
- diplopia (51)
- diagnosis (1487)
- dfe (3)
- deployed (26)
- denied (126)
- degeneration (126)
- decades (30)
- craniopharygioma (2)
- contributory (483)
- confusion (43)
- clearly (92)
- bromocriptine (7)
- bcva (2)
- attenuation (324)
- ant (7482)
- aneurysm (855)
- amaurosis (1)
- allergies (50)
- activation (15)
- activated (8)
- acth (15)
- 95 (206)
- 90 (326)
- 85 (172)
- 75 (204)
- 70 (283)
- 6 (5312)
- 53 (157)
- 45 (319)
- 40 (508)
- 30 (631)
- 28 (276)
- 27 (323)
- 26 (318)
- 15 (862)
- 0 (11370)
